Following low dose challenge, the Ccl24-cre: Tslpf/f mice ameliorated lesion progression (Fig. 7d) and controlled parasite burdens with a 30-fold reduction compared with WT and Ccl24-cre: Tslpf/+ mice at 12 weeks post-infection (Fig. 7e). The gene discussed is CCL24; the disease is infection.